Targets › SLCO1B1
1 program from 1 company in 1 trial: 1 Phase 4; Oncology; next expected readout Dec 2026.
Mediates the Na(+)-independent uptake of organic anions. Shows broad substrate specificity, can transport both organic anions such as bile acid taurocholate (cholyltaurine) and conjugated steroids (dehydroepiandrosterone 3-sulfate, 17-beta-glucuronosyl estradiol, and estrone 3-sulfate), as well as eicosanoids (prostaglandin E2, thromboxane B2, leukotriene C4, and leukotriene E4), and thyroid hormones…. (UniProt, Q9Y6L6)
Open in Phaseline: the race on SLCO1B1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Fujian Medical University Union Hospital | Silibinin Hepatoprotective agent; inhibits cancer cell growth and differentiation; stabilizes hepato | SLCO1B1 | Phase 4 | Acute Myeloid Leukemia | Dec 2026 |
Acute Myeloid Leukemia (1)
small molecule (1)
Fujian Medical University Union Hospital (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.